Summit Trail Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $916K | Buy |
2,809
+1,006
| +56% | +$328K | 0.02% | 510 |
|
|
2025
Q1 | $487K | Buy |
1,803
+518
| +40% | +$140K | 0.02% | 256 |
|
|
2024
Q4 | $302K | Buy |
1,285
+151
| +13% | +$35.5K | 0.01% | 289 |
|
|
2024
Q3 | $312K | Buy |
1,134
+205
| +22% | +$56.4K | 0.01% | 533 |
|
|
2024
Q2 | $226K | Buy |
+929
| New | +$226K | 0.01% | 560 |
|
|
2018
Q1 | – | Sell |
-289
| Closed | -$39K | – | 467 |
|
|
2017
Q4 | $39K | Buy |
+289
| New | +$39K | ﹤0.01% | 884 |
|